F-10/A: Profound Medical Corp. Files for US$150 Million Shelf Prospectus, Enabling Future Securities Offerings

Profound Medical Corp. has filed a short form base shelf prospectus and a related U.S. registration statement, allowing the company to offer up to US$150 million in various securities over the next 25 months.

Summary

• Profound Medical Corp. has filed a short form base shelf prospectus for up to US$150 million.
• This allows the company to offer common shares, warrants, debt securities, subscription receipts, and units.
• The securities may be offered separately or together, with terms determined by market conditions at the time of sale.
• The prospectus is valid for 25 months, including any amendments.
• The company has also filed a related registration statement with the U.S. Securities and Exchange Commission (SEC).
• Selling shareholders may also offer common shares under this prospectus, but not through at-the-market (ATM) distributions.
• The company's common shares are listed on the Toronto Stock Exchange (TSX) under the symbol PRN and on the Nasdaq under the symbol PROF.

Sentiment

Score: 7

Explanation: The document is primarily a regulatory filing related to a shelf prospectus, which is generally a positive sign for the company's financial flexibility. The document also highlights recent FDA clearances and ongoing clinical trials, which are positive developments. However, the document also acknowledges risks related to the company's financial performance and market acceptance of its products, which temper the overall sentiment.

Positives

• The shelf prospectus provides Profound Medical with financial flexibility to raise capital as needed.
• The company has a range of securities it can offer, allowing it to tailor offerings to market conditions.
• The company received FDA 510(k) clearance for the TULSA-AI module, Contouring Assistant, on May 14, 2024.
• The company announced three new CPT Category 1 Codes from the American Medical Association for TULSA to treat prostate diseases, which will be effective January 1, 2025.

Negatives

• The document itself does not explicitly state any negatives.
• However, it does mention risks related to the company's limited operating history and history of net losses, liquidity and financing needs, and ability to commercialize its approved products.

Risks

• The document references risks related to the company's limited operating history and history of net losses.
• There are risks related to the company's liquidity and financing needs.
• The company faces risks related to its ability to commercialize its approved products.
• Regulatory risks exist in obtaining and maintaining regulatory approvals.
• Clinical trial risks are present regarding the successful completion of clinical trials.
• The company faces risks related to managing growth and competition.
• Reliance on third parties, intellectual property, and product liability also pose risks.

Future Outlook

Profound Medical intends to use the funds raised for future product development, regulatory approvals, and commercialization of its approved products. The company is also focused on expanding the compatibility of its TULSA-PRO System with additional MRI brands and seeking regulatory approvals in additional international jurisdictions.

Industry Context

Profound Medical operates in the medical device industry, specifically focusing on image-guided ablation of diseased tissue. The company's TULSA-PRO system competes with other prostate cancer and BPH treatment options, including surgery, radiation therapy, and other minimally invasive procedures. The company is working to expand the clinical evidence supporting the use of its technologies for reimbursement and coverage by healthcare providers.

Comparison to Industry Standards

• Profound Medical's TULSA-PRO system competes with companies offering alternative prostate cancer treatments, such as Intuitive Surgical (da Vinci surgical system for robotic prostatectomy), EDAP TMS (HIFU technology for prostate ablation), and Boston Scientific (devices for BPH treatment).
• The company's focus on MRI-guided transurethral ultrasound ablation differentiates it from some competitors.
• The company's recurring revenue business model in the United States is similar to that of other medical device companies that charge on a per-procedure basis.

Stakeholder Impact

• Shareholders: The shelf prospectus provides the company with the ability to raise capital, which could be used to fund growth initiatives and increase shareholder value.
• Customers: The company's products, such as the TULSA-PRO system, offer a minimally invasive treatment option for prostate cancer and BPH, which could improve patient outcomes.
• Employees: The company's growth and success could create new job opportunities and provide employees with opportunities for advancement.

Next Steps

• Profound Medical may offer securities under the shelf prospectus as market conditions warrant.
• The company will continue to pursue regulatory approvals for its products in additional jurisdictions.
• The company will continue to recruit patients for the CAPTAIN trial and expects interim results in 1H 2025.
• Profound expects to file for FDA clearance for the TULSA-PRO contouring assistant in Q1 2024.
• Profound is seeking to gain FDA clearance for a BPH-specific application using the core TULSA technology in late 2024.

Key Dates

Keywords

shelf prospectus, securities, common shares, warrants, debt securities, subscription receipts, units, Profound Medical, TULSA-PRO, offering